Evaluate the safety of three doses of PFP-2 in ambulatory elderly subjects and determine and compare antibody titers to RSV as measured by EIA-F and Neutralization (Nt) assays to RSV-A and RSV-B after a single injection of one of three different dosage levels formulations (50, 25, or 10 ug) of PFP-2. We have completed one phase of this study and will be starting the next one after the influenza season has subsided as not to confound data.
Showing the most recent 10 out of 515 publications